×
About 4,314 results

ALLMedicine™ Immunodeficiencies Center

Research & Reviews  2,113 results

Death due to COVID-19 in an Infant with Combined Immunodeficiencies.
https://doi.org/10.2174/1871530320666201021142313
Endocrine, Metabolic & Immune Disorders Drug Targets; Ahanchian H, Moazzen N et. al.

Oct 22nd, 2020 - Novel coronavirus disease 2019 (COVID-19) has affected millions of people, which led to death especially in older cases with underlying diseases. Meanwhile pediatric patients with inherited defects of T cell should potentially be prone to viral di...

Everything a general paediatrician needs to know about primary immunodeficiencies.
https://doi.org/10.1111/jpc.15186
Journal of Paediatrics and Child Health References; Anderson AJ, Holland SM

Oct 16th, 2020 - Primary immunodeficiencies (PID) are a heterogenous group of inherited diseases, arising from inborn errors of immunity. Although typically managed by specialist immunologists, general paediatricians are often the first point of referral for patie...

High frequency of variants in genes associated with primary immunodeficiencies in patie...
https://doi.org/10.1136/annrheumdis-2020-218280
Annals of the Rheumatic Diseases; Sogkas G, Dubrowinskaja N et. al.

Oct 13th, 2020 - Treatment of rheumatic diseases requires immunomodulatory agents which can compromise antibody production. However, even in case of agents directly targeting B cells, a minority of patients develop hypogammaglobulinaemia, suggesting a genetic pred...

Rubella virus-associated chronic inflammation in primary immunodeficiency diseases.
https://doi.org/10.1097/ACI.0000000000000694
Current Opinion in Allergy and Clinical Immunology; Perelygina L, Icenogle J et. al.

Oct 12th, 2020 - The aim of this article is to summarize recent data on rubella virus (RuV) vaccine in chronic inflammation focusing on granulomas in individuals with primary immunodeficiencies (PIDs). The live attenuated RuV vaccine has been recently associated w...

Knock-out iPSCs for disease and therapy modeling of IL-10 associated primary immunodefi...
https://doi.org/10.1089/hum.2020.235
Human Gene Therapy; Sens J, Hoffmann D et. al.

Oct 7th, 2020 - Samples from patients with rare diseases, such as primary immunodeficiencies, are often limited, which hampers careful analysis of the pathomechanisms involved in immune cell dysregulation. To overcome this issue, induced pluripotent stem cells (i...

see more →

Guidelines  1 results

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
https://www.grifols.com/en/view-news/-/news/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies

Jul 4th, 2019 - Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is ...

see more →

Drugs  23 results see all →

Clinicaltrials.gov  2,151 results

Death due to COVID-19 in an Infant with Combined Immunodeficiencies.
https://doi.org/10.2174/1871530320666201021142313
Endocrine, Metabolic & Immune Disorders Drug Targets; Ahanchian H, Moazzen N et. al.

Oct 22nd, 2020 - Novel coronavirus disease 2019 (COVID-19) has affected millions of people, which led to death especially in older cases with underlying diseases. Meanwhile pediatric patients with inherited defects of T cell should potentially be prone to viral di...

Everything a general paediatrician needs to know about primary immunodeficiencies.
https://doi.org/10.1111/jpc.15186
Journal of Paediatrics and Child Health References; Anderson AJ, Holland SM

Oct 16th, 2020 - Primary immunodeficiencies (PID) are a heterogenous group of inherited diseases, arising from inborn errors of immunity. Although typically managed by specialist immunologists, general paediatricians are often the first point of referral for patie...

High frequency of variants in genes associated with primary immunodeficiencies in patie...
https://doi.org/10.1136/annrheumdis-2020-218280
Annals of the Rheumatic Diseases; Sogkas G, Dubrowinskaja N et. al.

Oct 13th, 2020 - Treatment of rheumatic diseases requires immunomodulatory agents which can compromise antibody production. However, even in case of agents directly targeting B cells, a minority of patients develop hypogammaglobulinaemia, suggesting a genetic pred...

Rubella virus-associated chronic inflammation in primary immunodeficiency diseases.
https://doi.org/10.1097/ACI.0000000000000694
Current Opinion in Allergy and Clinical Immunology; Perelygina L, Icenogle J et. al.

Oct 12th, 2020 - The aim of this article is to summarize recent data on rubella virus (RuV) vaccine in chronic inflammation focusing on granulomas in individuals with primary immunodeficiencies (PIDs). The live attenuated RuV vaccine has been recently associated w...

Knock-out iPSCs for disease and therapy modeling of IL-10 associated primary immunodefi...
https://doi.org/10.1089/hum.2020.235
Human Gene Therapy; Sens J, Hoffmann D et. al.

Oct 7th, 2020 - Samples from patients with rare diseases, such as primary immunodeficiencies, are often limited, which hampers careful analysis of the pathomechanisms involved in immune cell dysregulation. To overcome this issue, induced pluripotent stem cells (i...

see more →

News  23 results

Spotting immunodeficiency in the pediatric dermatology clinic
https://www.mdedge.com/dermatology/article/210332/rare-diseases/spotting-immunodeficiency-pediatric-dermatology-clinic?channel=39212
Jim Kling

Oct 17th, 2019 - SEATTLE – Immunodeficiency in children can look much like eczematous dermatitis. Be aware of this potential diagnosis.

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
https://www.grifols.com/en/view-news/-/news/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies

Jul 4th, 2019 - Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is ...

Novel transplant regimen improves survival in primary immunodeficiency
https://www.mdedge.com/hematology-oncology/article/195803/transplantation/novel-transplant-regimen-improves-survival?channel=50521
Sharon Worcester

Mar 6th, 2019 - HOUSTON – Allogeneic hematopoietic stem cell transplantation (allo-HCT) following a novel reduced-intensity conditioning regimen was largely successful in a heterogeneous cohort of 29 adults and children with primary immunodeficiency in a prospect.

A ‘highly effective’ strategy for haplo-HSCT
https://www.mdedge.com/hematology-oncology/article/184883/transplantation/highly-effective-strategy-haplo-hsct
Jen Smith

Jun 27th, 2018 - Daria Pagliara, MD, PhD STOCKHOLM—Researchers have identified a “highly effective” transplant strategy for pediatric patients with primary immunodeficiencies who lack a suitable HLA-compatible donor, according to a speaker at the 23rd Congress of.

FDA approves IVIG product for PI and chronic ITP
https://www.mdedge.com/hematology-oncology/article/186860/anemia/fda-approves-ivig-product-pi-and-chronic-itp
HT Staff

Feb 9th, 2017 - Vials of product Photo by Bill Branson The US Food and Drug Administration (FDA) has approved an intravenous immunoglobulin (IVIG) product (Gammaplex® 10%) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenia (ITP.

see more →

Patient Education  3 results see all →